Donepezil from Actavis first to eight EU markets as patents expire

Donepezil from Actavis first to eight EU markets as patents expire

Actavis today announced the launch of Donepezil in some of Europe's biggest markets, immediately after the patents expired. The conventional tablets were launched in Germany, France, Italy, Spain, the UK, Denmark, Sweden and Austria this week.

Donepezil tablets were developed by Actavis R&D and manufactured by Actavis in Malta.

Actavis is also bringing Donepezil oro-dispersible tablets to market following patent expiry in the UK and Sweden.

Actavis has already launched Donepezil in a number of patent-free markets.

Donepezil is indicated for the treatment of mild to moderately severe Alzheimer's disease. Donepezil Actavis is the generic equivalent of the brand product Aricept® from Pfizer.

The Brand product had sales in the EU of approximately EUR 475.6mln for the 12 months ending September 2011, according to IMS Health.


Actavis Group
Hjordis Arnadottir
Director - External Communications
Tel: +41 41 462 7300
E-mail: [email protected]


Suggested Articles

The FDA accused Pennsylvania's KVK-Tech of failing to install proper cleaning protocols at its oral solid-dose manufacturing plant in Newtown.

Today, AmerisourceBergen kicked off its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward manufacturers.

With interim data for its COVID-19 vaccine still in the works, Pfizer is holding on to hope that it can still roll the shot out this year in the U.S.